Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis

Author:

Shi Wanliang1,Zhang Xuelian2,Jiang Xin3,Yuan Haiming2,Lee Jong Seok4,Barry Clifton E.5,Wang Honghai2,Zhang Wenhong6,Zhang Ying16

Affiliation:

1. W. Harry Feinstone Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.

2. State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China.

3. Department of Medical Microbiology and Immunology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.

4. International Tuberculosis Research Center, Changwon 475-1, Korea.

5. Tuberculosis Research Section, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, MD 20892, USA.

6. Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China.

Abstract

The target of a first-line tuberculosis drug that acts against persister bacteria is identified.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference34 articles.

1. World Health Organization (WHO) WHO Report 2010: Global Tuberculosis Control (2010).

2. The action of antituberculosis drugs in short-course chemotherapy

3. Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media;Tarshis M. S.;Am. Rev. Tuberc.,1953

4. Activation of pyrazinamide and nicotinamide in acidic environments in vitro;McDermott W.;Am. Rev. Tuberc.,1954

5. MICROBIAL PERSISTENCE

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3